AVENUE THERAPEUTICS, INC. 8-K

What Happened Avenue Therapeutics, Inc. announced the results of its 2025 annual meeting of stockholders held virtually on December 30, 2025. Shareholders elected six directors to hold office until the 2026 annual meeting and ratified KPMG LLP as the company’s independent registered public accounting firm for the year ending December 31, 2025. These matters were described in Avenue’s definitive proxy statement filed December 5, 2025.

Key Details

• Meeting date & format: December 30, 2025, held via an online virtual meeting platform; proxy filed December 5, 2025.
• Election results: Six directors elected — Jay Kranzler, M.D., Ph.D.; Faith Charles; Neil Herskowitz; Alexandra MacLean, M.D.; Curtis Oltmans; and Lindsay A. Rosenwald, M.D. Each received about 3.861–3.862 million votes FOR and about 105,936–106,438 votes WITHHELD.
• Auditor ratification: KPMG LLP was ratified with 3,862,335 votes FOR, 104,651 votes AGAINST and 1,010 abstentions.
• Record date and voting power: As of the November 25, 2025 record date there were 3,183,426 common shares outstanding (3,183,426 votes) and 250,000 Class A Preferred shares outstanding, which were entitled to an aggregate of 3,500,000 votes under the company’s certificate of incorporation.

Why It Matters For investors, the filing confirms board continuity—Avenue’s incumbent slate was re-elected—so strategic and governance plans are likely to proceed without board turnover. Ratification of KPMG maintains continuity in the company’s external audit for 2025, which is relevant for upcoming financial reporting and investor confidence. The vote totals and the preferred shares’ voting structure are factual details investors can use to assess shareholder support and control.